ÂÜÀòÂÒÂ×

Wen Jing Chen has over 9 years of work experience, starting in 2011 as an Associate at Mercer Management Consulting. From 2014 to 2016, Chen worked as a Director at a company called "²æÉÕ". In 2016, Chen joined Sunovion Pharmaceuticals as a Senior Director, where they were responsible for leading and managing the Lunesta and Xopenex franchises. In 2018, Chen moved to the University of Michigan Medical School as the Director of Business Development. Currently, Chen holds the position of Chief Operating Officer at ONL Therapeutics, starting in June 2019.

Wen Jing Chen completed their A.B. in Psychobiology from Harvard University between 2004 and 2008. Later, they pursued an MBA in Business Administration and Management, General from Harvard Business School during the period of 2009 to 2010.